These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23427335)

  • 1. Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
    Budman DR; Calabro A; Rosen L; Lesser M
    Anticancer Drugs; 2012 Mar; 23(3):272-9. PubMed ID: 23427335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
    Pegram MD; Konecny GE; O'Callaghan C; Beryt M; Pietras R; Slamon DJ
    J Natl Cancer Inst; 2004 May; 96(10):739-49. PubMed ID: 15150302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
    Budman DR; Calabro A
    Oncology; 2006; 70(2):147-53. PubMed ID: 16645328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.
    Budman DR; Tai J; Calabro A; John V
    Invest New Drugs; 2011 Dec; 29(6):1224-9. PubMed ID: 20533074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
    Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
    Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro.
    Budman DR; Tai J; Calabro A
    Breast Cancer Res Treat; 2007 Jul; 104(1):93-101. PubMed ID: 17004104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.
    Konecny GE; Pegram MD
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 12):32-6. PubMed ID: 15685824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
    Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y
    Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
    Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
    PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
    Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
    Wang G; Edwards H; Caldwell JT; Buck SA; Qing WY; Taub JW; Ge Y; Wang Z
    PLoS One; 2013; 8(9):e76662. PubMed ID: 24098799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
    Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
    Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promising combination therapies with gemcitabine.
    Robinson BW; Ostruszka L; Im MM; Shewach DS
    Semin Oncol; 2004 Apr; 31(2 Suppl 5):2-12. PubMed ID: 15199526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.
    Fuino L; Bali P; Wittmann S; Donapaty S; Guo F; Yamaguchi H; Wang HG; Atadja P; Bhalla K
    Mol Cancer Ther; 2003 Oct; 2(10):971-84. PubMed ID: 14578462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.
    Lachenmayer A; Toffanin S; Cabellos L; Alsinet C; Hoshida Y; Villanueva A; Minguez B; Tsai HW; Ward SC; Thung S; Friedman SL; Llovet JM
    J Hepatol; 2012 Jun; 56(6):1343-50. PubMed ID: 22322234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling.
    Wang L; Syn NL; Subhash VV; Any Y; Thuya WL; Cheow ESH; Kong L; Yu F; Peethala PC; Wong AL; Laljibhai HJ; Chinnathambi A; Ong PS; Ho PC; Sethi G; Yong WP; Goh BC
    Cancer Lett; 2018 Mar; 417():152-160. PubMed ID: 29306016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.
    Teo EC; Valdez BC; Ji J; Li Y; Liu Y; Brammer JE; Hosing C; Nieto Y; Champlin RE; Andersson BS
    Leuk Lymphoma; 2016 Nov; 57(11):2644-52. PubMed ID: 26980288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells.
    Azrak RG; Frank CL; Ling X; Slocum HK; Li F; Foster BA; Rustum YM
    Mol Cancer Ther; 2006 Oct; 5(10):2540-8. PubMed ID: 17041098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
    Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
    Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
    Konecny G; Untch M; Slamon D; Beryt M; Kahlert S; Felber M; Langer E; Lude S; Hepp H; Pegram M
    Breast Cancer Res Treat; 2001 Jun; 67(3):223-33. PubMed ID: 11561768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.